Michele Togno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michele Togno has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Gardenali Yukihara
Paul Scherrer Institute (PSI)
4 shared publications - Jeppe Brage Christensen
Paul Scherrer Institute (PSI)
4 shared publications - Mads Lykke Jensen
Paul Scherrer Institute (PSI)
2 shared publications - Sairos Safai
Paul Scherrer Inst, Villigen, Switzerland
2 shared publications A J Lomax
Center for Proton Therapy, Paul Scherrer Institute, Villigen PSI, SWITZERLAND
1 shared publicationA. Dütschler
1 shared publication
Latest Publications
- Open Access
- 16 November 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (22) , 225003
Experimental verification of clinical dose and LET maps for LET-informed proton therapy
Objective. Linear energy transfer (LET)-informed proton therapy has the potential to improve biological treatment planning beyond the conventional assumption of a constant relative biological effectiveness. Its clinical translation, however, requires experimental tools capable of verifying spatially resolved dose and dose-averaged LET ( LET ― D ) distributions under clinically relevant conditions. We recently introduced an optically stimulated luminescence film-based detector system that simultaneously measures two-dimensional (2D) absorbed dose and LET ― D . This work provides a first assessment of the system for verifying dose and LET ― D distributions from clinical proton therapy plans. Approach. The system was tested at two proton therapy centers, ranging from simple uniform fields to more complex geometries, including Bragg curve measurements and a clinically realistic anthropomorphic head phantom treatment plan. Measured dose and LET ― D distributions were compared against commercial treatment planning system (TPS) calculations and, for selected fields, to external Monte Carlo particle transport simulations due to the absence of traceability of LET ― D . For non-uniform irradiations, agreement was assessed using gamma analysis with 3%/2 mm and 5%/2 mm criteria for dose and LET ― D , respectively. Main results. For uniform fields, measured dose and LET ― D distributions generally agreed with TPS and independent Monte Carlo simulations across a range of clinically relevant irradiation conditions. In the Bragg curve measurement, gamma pass rates were 96.6% for dose and 99.7% for LET ― D , with the largest dose discrepancy observed near the Bragg peak, consistent with a current over-correction of detector quenching in high-LET regions to be improved in future work. In the anthropomorphic phantom, gamma pass rates ranged from 75% to 100% for dose and from 45% to 95% for LET ― D , with a single layer showing a sub-50% pass rate for LET ― D . Failing regions were confined to high-dose superior layers for dose and distal-edge, high-LET regions for LET ― D . Significance. The presented results support the detector system’s use as an experimental benchmarking tool for TPS-calculated dose and LET ― D maps. Given this and the system’s ability to simultaneously measure 2D dose and LET ― D maps with high spatial resolution and minimal field perturbation, the system shows promise for future commissioning workflows for LET-informed proton therapy.
- 16 November 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (22) , 225003
Open AccessExperimental verification of clinical dose and LET maps for LET-informed proton therapy
Objective. Linear energy transfer (LET)-informed proton therapy has the potential to improve biological treatment planning beyond the conventional assumption of a constant relative biological effectiveness. Its clinical translation, however, requires experimental tools capable of verifying spatially resolved dose and dose-averaged LET ( LET ― D ) distributions under clinically relevant conditions. We recently introduced an optically stimulated luminescence film-based detector system that simultaneously measures two-dimensional (2D) absorbed dose and LET ― D . This work provides a first assessment of the system for verifying dose and LET ― D distributions from clinical proton therapy plans. Approach. The system was tested at two proton therapy centers, ranging from simple uniform fields to more complex geometries, including Bragg curve measurements and a clinically realistic anthropomorphic head phantom treatment plan. Measured dose and LET ― D distributions were compared against commercial treatment planning system (TPS) calculations and, for selected fields, to external Monte Carlo particle transport simulations due to the absence of traceability of LET ― D . For non-uniform irradiations, agreement was assessed using gamma analysis with 3%/2 mm and 5%/2 mm criteria for dose and LET ― D , respectively. Main results. For uniform fields, measured dose and LET ― D distributions generally agreed with TPS and independent Monte Carlo simulations across a range of clinically relevant irradiation conditions. In the Bragg curve measurement, gamma pass rates were 96.6% for dose and 99.7% for LET ― D , with the largest dose discrepancy observed near the Bragg peak, consistent with a current over-correction of detector quenching in high-LET regions to be improved in future work. In the anthropomorphic phantom, gamma pass rates ranged from 75% to 100% for dose and from 45% to 95% for LET ― D , with a single layer showing a sub-50% pass rate for LET ― D . Failing regions were confined to high-dose superior layers for dose and distal-edge, high-LET regions for LET ― D . Significance. The presented results support the detector system’s use as an experimental benchmarking tool for TPS-calculated dose and LET ― D maps. Given this and the system’s ability to simultaneously measure 2D dose and LET ― D maps with high spatial resolution and minimal field perturbation, the system shows promise for future commissioning workflows for LET-informed proton therapy.
- Open Access
- 24 October 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (21) , 215008
Achieving high-resolution spatial mapping of dose and linear energy transfer in ion-beam therapy
Objective. We present a novel detector system capable of simultaneously obtaining two-dimensional (2D) dose and linear energy transfer (LET) maps from Al 2 O 3 films of sizes up to ( 190 × 190 ) mm 2 using optically stimulated luminescence (OSL). Approach. The system is based on the OSL from doped Al 2 O 3 films measured using pulsed stimulation and time-resolved OSL detection. The system was calibrated in 1 H-, 4 He-, and 12 C-ion beams. The minimal detectable dose (MDD), response homogeneity, pixel cross-stimulation, and precision were also investigated. To demonstrate the system’s performance, 2D maps of dose and LET of a proton Bragg curve were measured. Main results. The system was demonstrated to be capable of obtaining absorbed dose and LET 2D maps with a spatial resolution set to ( 1.0 × 1.0 ) mm 2 . The system was calibrated over a clinically relevant range of LET values and characterized through assessment of MDD ( < 25 mGy), readout protocols, response homogeneity, precision, and relative detector efficiency. Dose and LET were found to be measurable with precisions of 3.2% and 10%, respectively. Significance. To our knowledge, this is the first passive detector system capable of measuring LET and dose simultaneously in 2D with a 1.0 mm 2 spatial resolution requiring no prior information. Such properties are required to experimentally validate simulated dose and LET distributions in ion-beam therapy, paving the way for sub-mm mapping of radiation-induced relative biological effectiveness.
- 24 October 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (21) , 215008
Open AccessAchieving high-resolution spatial mapping of dose and linear energy transfer in ion-beam therapy
Objective. We present a novel detector system capable of simultaneously obtaining two-dimensional (2D) dose and linear energy transfer (LET) maps from Al 2 O 3 films of sizes up to ( 190 × 190 ) mm 2 using optically stimulated luminescence (OSL). Approach. The system is based on the OSL from doped Al 2 O 3 films measured using pulsed stimulation and time-resolved OSL detection. The system was calibrated in 1 H-, 4 He-, and 12 C-ion beams. The minimal detectable dose (MDD), response homogeneity, pixel cross-stimulation, and precision were also investigated. To demonstrate the system’s performance, 2D maps of dose and LET of a proton Bragg curve were measured. Main results. The system was demonstrated to be capable of obtaining absorbed dose and LET 2D maps with a spatial resolution set to ( 1.0 × 1.0 ) mm 2 . The system was calibrated over a clinically relevant range of LET values and characterized through assessment of MDD ( < 25 mGy), readout protocols, response homogeneity, precision, and relative detector efficiency. Dose and LET were found to be measurable with precisions of 3.2% and 10%, respectively. Significance. To our knowledge, this is the first passive detector system capable of measuring LET and dose simultaneously in 2D with a 1.0 mm 2 spatial resolution requiring no prior information. Such properties are required to experimentally validate simulated dose and LET distributions in ion-beam therapy, paving the way for sub-mm mapping of radiation-induced relative biological effectiveness.
- Open Access
- 17 February 2023
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 68 (4) , 045017
Characterization of LiF:Mg,Ti thermoluminescence detectors in low-LET proton beams at ultra-high dose rates
Objective. This work aims at characterizing LiF:Mg,Ti thermoluminescence detectors (TLDs) for dosimetry of a 250 MeV proton beam delivered at ultra-high dose rates (UHDR). Possible dose rate effects in LiF:Mg,Ti, as well as its usability for dosimetry of narrow proton beams are investigated. Approach. LiF:Mg,Ti (TLD-100TM Microcubes, 1 mm × 1 mm × 1 mm) was packaged in matrices of 5 × 5 detectors. The center of each matrix was irradiated with single-spot low-LET (energy >244 MeV) proton beam in the (1–4500) Gy s−1 average dose rates range. A beam reconstruction procedure was applied to the detectors irradiated at the highest dose rate (Gaussian beam sigma Main results. The lateral beam spread obtained from the beam reconstruction agreed with the one derived from the radiochromic film measurements. No dose rates effects were observed in LiF:Mg,Ti for the investigated dose rates within 3% (k = 1). On average, the dose response of the TLDs agreed with the reference detectors within their uncertainties. The largest deviation (−5%) was measured at 4500 Gy s−1. Significance. The dose rate independence of LiF:Mg,Ti TLDs makes them suitable for dosimetry of UHDR proton beams. Additionally, the combination of a matrix of TLDs and the beam reconstruction can be applied to determine the beam profile of narrow proton beams.
- 17 February 2023
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 68 (4) , 045017
Open AccessCharacterization of LiF:Mg,Ti thermoluminescence detectors in low-LET proton beams at ultra-high dose rates
Objective. This work aims at characterizing LiF:Mg,Ti thermoluminescence detectors (TLDs) for dosimetry of a 250 MeV proton beam delivered at ultra-high dose rates (UHDR). Possible dose rate effects in LiF:Mg,Ti, as well as its usability for dosimetry of narrow proton beams are investigated. Approach. LiF:Mg,Ti (TLD-100TM Microcubes, 1 mm × 1 mm × 1 mm) was packaged in matrices of 5 × 5 detectors. The center of each matrix was irradiated with single-spot low-LET (energy >244 MeV) proton beam in the (1–4500) Gy s−1 average dose rates range. A beam reconstruction procedure was applied to the detectors irradiated at the highest dose rate (Gaussian beam sigma Main results. The lateral beam spread obtained from the beam reconstruction agreed with the one derived from the radiochromic film measurements. No dose rates effects were observed in LiF:Mg,Ti for the investigated dose rates within 3% (k = 1). On average, the dose response of the TLDs agreed with the reference detectors within their uncertainties. The largest deviation (−5%) was measured at 4500 Gy s−1. Significance. The dose rate independence of LiF:Mg,Ti TLDs makes them suitable for dosimetry of UHDR proton beams. Additionally, the combination of a matrix of TLDs and the beam reconstruction can be applied to determine the beam profile of narrow proton beams.
- Open Access
- 18 May 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-10
Improved simultaneous LET and dose measurements in proton therapy
The objective of this study was to improve the precision of linear energy transfer (LET) measurements using $$\text {Al}_2\text {O}_3\text {:C}$$ optically stimulated luminescence detectors (OSLDs) in proton beams, and, with that, improve OSL dosimetry by correcting the readout for the LET-dependent ionization quenching. The OSLDs were irradiated in spot-scanning proton beams at different doses for fluence-averaged LET values in the (0.4–6.5) $$\hbox {keV}\, \upmu \hbox {m}^{-1}$$ range (in water). A commercial automated OSL reader with a built-in beta source was used for the readouts, which enabled a reference irradiation and readout of each OSLD to establish individual corrections. Pulsed OSL was used to separately measure the blue (F-center) and UV ( $$F^+$$ -center) emission bands of $$\text {Al}_2\text {O}_3\text {:C}$$ and the ratio between them (UV/blue signal) was used for the LET measurements. The average deviation between the simulated and measured LET values along the central beam axis amounts to 5.5% if both the dose and LET are varied, but the average deviation is reduced to 3.5% if the OSLDs are irradiated with the same doses. With the measurement procedure and automated equipment used here, the variation in the signals used for LET estimates and quenching-corrections is reduced from 0.9 to 0.6%. The quenching-corrected OSLD doses are in agreement with ionization chamber measurements within the uncertainties. The automated OSLD corrections are demonstrated to improve the LET estimates and the ionization quenching-corrections in proton dosimetry for a clinically relevant energy range up to 230 MeV. It is also for the first time demonstrated how the LET can be estimated for different doses.- 18 May 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-10
Open AccessImproved simultaneous LET and dose measurements in proton therapy
The objective of this study was to improve the precision of linear energy transfer (LET) measurements using $$\text {Al}_2\text {O}_3\text {:C}$$ optically stimulated luminescence detectors (OSLDs) in proton beams, and, with that, improve OSL dosimetry by correcting the readout for the LET-dependent ionization quenching. The OSLDs were irradiated in spot-scanning proton beams at different doses for fluence-averaged LET values in the (0.4–6.5) $$\hbox {keV}\, \upmu \hbox {m}^{-1}$$ range (in water). A commercial automated OSL reader with a built-in beta source was used for the readouts, which enabled a reference irradiation and readout of each OSLD to establish individual corrections. Pulsed OSL was used to separately measure the blue (F-center) and UV ( $$F^+$$ -center) emission bands of $$\text {Al}_2\text {O}_3\text {:C}$$ and the ratio between them (UV/blue signal) was used for the LET measurements. The average deviation between the simulated and measured LET values along the central beam axis amounts to 5.5% if both the dose and LET are varied, but the average deviation is reduced to 3.5% if the OSLDs are irradiated with the same doses. With the measurement procedure and automated equipment used here, the variation in the signals used for LET estimates and quenching-corrections is reduced from 0.9 to 0.6%. The quenching-corrected OSLD doses are in agreement with ionization chamber measurements within the uncertainties. The automated OSLD corrections are demonstrated to improve the LET estimates and the ionization quenching-corrections in proton dosimetry for a clinically relevant energy range up to 230 MeV. It is also for the first time demonstrated how the LET can be estimated for different doses. - 25 February 2022
- Published by Elsevier in Physica Medica
- Vol. 94, S33-S34
FLASH in the Clinic Track (Oral Presentations) ULTRA-HIGH DOSE RATE DOSIMETRY FOR PRE-CLINICAL EXPERIMENTS WITH MM-SMALL PROTON FIELDS
- 25 February 2022
- Published by Elsevier in Physica Medica
- Vol. 94, S33-S34
FLASH in the Clinic Track (Oral Presentations) ULTRA-HIGH DOSE RATE DOSIMETRY FOR PRE-CLINICAL EXPERIMENTS WITH MM-SMALL PROTON FIELDS